Acorda Therapeutics Inc. (ACOR)

18.41
0.89 4.60
NASDAQ : Health Technology
Prev Close 19.30
Open 19.47
Day Low/High 18.40 / 19.53
52 Wk Low/High 15.60 / 36.35
Volume 171.72K
Avg Volume 804.90K
Exchange NASDAQ
Shares Outstanding 47.56M
Market Cap 875.07M
EPS -4.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Acorda Third Quarter 2018 Update: Webcast/Conference Call Scheduled For October 31, 2018

Acorda Third Quarter 2018 Update: Webcast/Conference Call Scheduled For October 31, 2018

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its third quarter 2018 update and financial results on Wednesday, October 31 at 8:30 a.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: IMO, RDC Downgrades: ACOR, CUZ, VBFC, VSAT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Relative Strength Alert For Acorda Therapeutics

Relative Strength Alert For Acorda Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Acorda To Present Data For INBRIJA™ (levodopa Inhalation Powder) At International Congress Of Parkinson's Disease And Movement Disorders

Acorda To Present Data For INBRIJA™ (levodopa Inhalation Powder) At International Congress Of Parkinson's Disease And Movement Disorders

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will present a new post-hoc efficacy analysis from SPAN-PD, the pivotal Phase 3 trial of INBRIJA, at the upcoming International Congress of Parkinson's Disease and Movement Disorders ® taking place October 5-9, 2018...

Acorda Announces FDA Extends INBRIJA NDA Review Period

Acorda Announces FDA Extends INBRIJA NDA Review Period

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.

U.S. Court Of Appeals For The Federal Circuit Upholds District Court's Decision To Invalidate AMPYRA® (dalfampridine) Patents

U.S. Court Of Appeals For The Federal Circuit Upholds District Court's Decision To Invalidate AMPYRA® (dalfampridine) Patents

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the United States Court of Appeals for the Federal Circuit, by a 2-1 vote, has upheld the United States District Court for the District of Delaware's decision to invalidate four AMPYRA patents.

Acorda Announces Management Transitions

Acorda Announces Management Transitions

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Rick Batycky, Ph.

Acorda Provides Financial And Pipeline Update For Second Quarter 2018

Acorda Provides Financial And Pipeline Update For Second Quarter 2018

Acorda Therapeutics, Inc. (Nasdaq: ACOR) provided a financial and pipeline update for the quarter ended June 30, 2018.

Acorda Second Quarter Update: Webcast/Conference Call Scheduled For August 2, 2018

Acorda Second Quarter Update: Webcast/Conference Call Scheduled For August 2, 2018

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its second quarter 2018 update and financial results on Thursday, August 2 at 8:30 a.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACOR, LMST, ORCL, VALE Downgrades: EXFO, NXRT, ONP Initiations: BLNK Read on to get TheStreet Quant Ratings' detailed report:

Acorda To Present Data For INBRIJA™ (levodopa Inhalation Powder) At 2nd Pan American Parkinson's Disease And Movement Disorders Congress

Acorda To Present Data For INBRIJA™ (levodopa Inhalation Powder) At 2nd Pan American Parkinson's Disease And Movement Disorders Congress

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present four encore INBRIJA posters at the upcoming 2 nd Pan American Parkinson's Disease and Movement Disorders Congress taking place June 22-24, 2018 in Miami, Florida.

Acorda Announces EMA Validation Of The MAA Submission For INBRIJA™ (levodopa Inhalation Powder)

Acorda Announces EMA Validation Of The MAA Submission For INBRIJA™ (levodopa Inhalation Powder)

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the European Medicines Agency (EMA) has completed formal validation of Acorda's Marketing Authorization Application (MAA) for INBRIJA.

Acorda Therapeutics Reaches Analyst Target Price

In recent trading, shares of Acorda Therapeutics Inc have crossed above the average analyst 12-month target price of $23.29, changing hands for $23.55/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Acorda Provides Financial And Pipeline Update For First Quarter 2018

Acorda Provides Financial And Pipeline Update For First Quarter 2018

Acorda Therapeutics, Inc. (Nasdaq: ACOR) provided a financial and pipeline update for the quarter ended March 31, 2018.

First Week of ACOR May 18th Options Trading

Investors in Acorda Therapeutics Inc saw new options become available this week, for the May 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACOR options chain for the new May 18th contracts and identified one put and one call contract of particular interest.

Acorda Files Marketing Authorization Application For INBRIJA™ (levodopa Inhalation Powder)

Acorda Files Marketing Authorization Application For INBRIJA™ (levodopa Inhalation Powder)

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for INBRIJA.

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.

Acorda Rallies Parkinson's Community In First-of-Its-Kind Initiative To Foster Better Conversations About Parkinson's Symptoms

Acorda Rallies Parkinson's Community In First-of-Its-Kind Initiative To Foster Better Conversations About Parkinson's Symptoms

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today unveiled the "Live Well.

Acorda Therapeutics To Present At Oppenheimer Healthcare Conference

Acorda Therapeutics To Present At Oppenheimer Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Andrew Hindman, Acorda's Chief Business Development Officer, will present at the Oppenheimer Healthcare Conference on Tuesday, March 20 at 11:30am.

Acorda To Present At Cowen Health Care Conference

Acorda To Present At Cowen Health Care Conference

Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Ron Cohen, M.

Acorda Enters Into Cooperation Agreement With Scopia

Acorda Enters Into Cooperation Agreement With Scopia

Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it has entered into a cooperation agreement with Scopia Capital Management LP.

First Week of October 19th Options Trading For Acorda Therapeutics (ACOR)

First Week of October 19th Options Trading For Acorda Therapeutics (ACOR)

Investors in Acorda Therapeutics Inc saw new options become available this week, for the October 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Acorda Announces FDA Acceptance Of New Drug Application For INBRIJA™ (levodopa Inhalation Powder)

Acorda Announces FDA Acceptance Of New Drug Application For INBRIJA™ (levodopa Inhalation Powder)

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.

Acorda Provides Financial And Pipeline Update For Fourth Quarter And Year End 2017

Acorda Provides Financial And Pipeline Update For Fourth Quarter And Year End 2017

Acorda Therapeutics, Inc. (Nasdaq: ACOR) provided a financial and pipeline update for the fourth quarter and full year ended December 31, 2017.

Acorda Therapeutics To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Acorda Therapeutics To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Ron Cohen, M.

Acorda Fourth Quarter/Year End 2017 Update

Acorda Fourth Quarter/Year End 2017 Update

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its fourth quarter 2017 financial results and pipeline updates on Thursday, February 15 at 8:30 a.

Notable Thursday Option Activity: ACOR, VHC, TREE

Notable Thursday Option Activity: ACOR, VHC, TREE

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Acorda Therapeutics Inc , where a total volume of 4,420 contracts has been traded thus far today, a contract volume which is representative of approximately 442,000 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 74.2% of ACOR's average daily trading volume over the past month, of 595,775 shares.

SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Class Action Lawsuit Filed Against Acorda Therapeutics, Inc.

SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Class Action Lawsuit Filed Against Acorda Therapeutics, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Acorda Therapeutics, Inc.

TheStreet Quant Rating: D+ (Sell)